Allscripts buys Practice Fusion for $100M

Once expected to be valued at $1.5 billion, cloud-based electronic health records vendor Practice Fusion will be acquired by larger EHR provider Allscripts for $100 million in cash.

Just two years ago, Practice Fusion had hired JPMorgan Chase to explore going public, estimating its revenue in 2018 would be as high as $181 million. Since then, however, the rush of spending to meet Meaningful Use requirements has slowed considerably and the EHR market has consolidated around a few big vendors, leaving little room for smaller startups like Practice Fusion.

For Allscripts, the purchase expands its reach into more outpatient settings with the 30,000 small, independent physician practices using Practice Fusion platforms, including EHR, patient portals and practice management software.

“Combined with Practice Fusion, we expect Allscripts to continue to drive innovation in addressing gaps-in-care, improving clinical outcomes and real-world-evidence research,” Allscripts president Rick Poulton said in a statement. “Plus, Practice Fusion’s affordable EHR technology supports traditionally hard-to-reach independent physician practices, and its cloud-based infrastructure aligns with Allscripts forward vision for solution delivery.”

In 2015, Practice Fusion owned the largest market share for solo practices at 15 percent.

Allscripts expects the deal to close in the first quarter of 2018. It’s the second major acquisition for the Chicago-based company in the past six months following its $185 million deal for McKesson’s health IT business. Last year, Allscripts was ranked fourth in revenue related to EHR hardware behind Cerner, McKesson and Epic.

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.